JP7141417B2 - ヒトfkrpタンパク質をコードする新規ポリヌクレオチド - Google Patents
ヒトfkrpタンパク質をコードする新規ポリヌクレオチド Download PDFInfo
- Publication number
- JP7141417B2 JP7141417B2 JP2019572563A JP2019572563A JP7141417B2 JP 7141417 B2 JP7141417 B2 JP 7141417B2 JP 2019572563 A JP2019572563 A JP 2019572563A JP 2019572563 A JP2019572563 A JP 2019572563A JP 7141417 B2 JP7141417 B2 JP 7141417B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fkrp
- sequence
- vector
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000040430 polynucleotide Human genes 0.000 title claims description 64
- 108091033319 polynucleotide Proteins 0.000 title claims description 64
- 239000002157 polynucleotide Substances 0.000 title claims description 64
- 101000846198 Homo sapiens Ribitol 5-phosphate transferase FKRP Proteins 0.000 title claims description 32
- 102000056880 human FKRP Human genes 0.000 title description 26
- 239000013598 vector Substances 0.000 claims description 62
- 102100031774 Ribitol 5-phosphate transferase FKRP Human genes 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 39
- 208000033534 FKRP-related limb-girdle muscular dystrophy R9 Diseases 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 15
- 239000013607 AAV vector Substances 0.000 claims description 13
- 201000006793 Walker-Warburg syndrome Diseases 0.000 claims description 12
- 208000034373 type A muscular dystrophy-dystroglycanopathy Diseases 0.000 claims description 11
- 102400000310 Alpha-dystroglycan Human genes 0.000 claims description 9
- 108010071885 Dystroglycans Proteins 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 241000702421 Dependoparvovirus Species 0.000 claims description 5
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 5
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 5
- 208000014644 Brain disease Diseases 0.000 claims description 4
- 208000032274 Encephalopathy Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 3
- 101800000379 Alpha-dystroglycan Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 53
- 101710087595 Ribitol 5-phosphate transferase FKRP Proteins 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 108091081024 Start codon Proteins 0.000 description 33
- 201000010099 disease Diseases 0.000 description 30
- 239000002773 nucleotide Substances 0.000 description 30
- 125000003729 nucleotide group Chemical group 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 238000000034 method Methods 0.000 description 27
- 230000000692 anti-sense effect Effects 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 230000013595 glycosylation Effects 0.000 description 12
- 238000006206 glycosylation reaction Methods 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- YNVAHBUBGBLIEY-WGDLNXRISA-N (1e,4e)-1,5-bis(2-hydroxyphenyl)penta-1,4-dien-3-one Chemical compound OC1=CC=CC=C1\C=C\C(=O)\C=C\C1=CC=CC=C1O YNVAHBUBGBLIEY-WGDLNXRISA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 101150024875 hbb2 gene Proteins 0.000 description 10
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 8
- 210000000234 capsid Anatomy 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 210000003414 extremity Anatomy 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000002027 skeletal muscle Anatomy 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 101150058676 Fkrp gene Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000037433 frameshift Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000007910 systemic administration Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108091033380 Coding strand Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108020005350 Initiator Codon Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 208000017081 Qualitative or quantitative defects of alpha-dystroglycan Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 101000928044 Homo sapiens Desmin Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108091029523 CpG island Proteins 0.000 description 2
- VJDOAZKNBQCAGE-LMVFSUKVSA-N D-ribitol 5-phosphate Chemical compound OC[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O VJDOAZKNBQCAGE-LMVFSUKVSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010044052 Desmin Proteins 0.000 description 2
- 102100036912 Desmin Human genes 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000051366 Glycosyltransferases Human genes 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000005045 desmin Anatomy 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000013646 rAAV2 vector Substances 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- 101150079978 AGRN gene Proteins 0.000 description 1
- 102100026656 Actin, alpha skeletal muscle Human genes 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 241000649047 Adeno-associated virus 12 Species 0.000 description 1
- 102100040026 Agrin Human genes 0.000 description 1
- 108700019743 Agrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101710153311 Hemoglobin subunit beta-2 Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 101000834207 Homo sapiens Actin, alpha skeletal muscle Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100120173 Mus musculus Fkrp gene Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 description 1
- 101710087566 Ribitol-5-phosphate transferase FKTN Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000013184 cardiac magnetic resonance imaging Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000012625 in-situ measurement Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000011042 muscle-eye-brain disease Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- -1 rRNA Proteins 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Description
別の定義をしない限り、本書に使用する技術用語および科学用語はいずれも、当業者に通常理解されるのと同じ意味を有する。本書に使用する用語は、単に特定の態様を説明することを目的とするものであり、限定が意図されるものではない。
本発明は、フクチン関連タンパク質(FKRP)コード領域に含まれる追加のフレームシフト開始コドンの禁止によって、FKRP発現が増加するという知見に基づく。
メインのORFは、メチオニン(MまたはMet)をコードするATG(配列番号2のヌクレオチド1~3)によって位置1で始まる。当該ORFは1488の塩基またはヌクレオチドからなり、495アミノ酸のタンパク質をコードし、終止コドンTGAで終わる。インフェーズ、すなわちインフレームであるさらなるORFは、メチオニン(MまたはMet)をコードするATGによって、位置430(配列番号2のヌクレオチド430~432)および位置1279(配列番号2のヌクレオチド1279~1281)で始まる。しかしながら、それを変更することは、ATG以外に古典的にメチオニンをコードするコドンがないゆえに、不可能である。
・位置429(配列番号2のヌクレオチド429~431)、位置819(配列番号2のヌクレオチド819~821)、および位置1431(配列番号2のヌクレオチド1431~1433)における、アンチセンス方向のATGに対応するCAT;
・位置545(配列番号2のヌクレオチド545~547)における、センス方向のATG。
一態様において、GC含量が変更され、好ましくは低下される。好ましくは、本発明のポリヌクレオチドのGC含量は、配列番号2のGC含量に対して5%未満、または配列番号2のGC含量に対して10%を超えて低下される。GおよびC塩基のAまたはTによる置換によって、アミノ酸配列は保存されるべきであり、好ましくはさらなる開始コドンの導入はなされない。
またはAAV2/9ベクターである。より好ましくは、本発明のベクターは、AAV9ベクターまたはAAV2/9ベクターである。
・転写安定化のための配列、例えばヘモグロビン(HBB2)のイントロン1。配列番号14に示されるように、該HBB2イントロンは好ましくは、翻訳開始を改善するように、mRNAにおいてAUG開始コドンの前に含まれるコンセンサスKozak配列につなげられる;
・ポリアデニル化シグナル、例えば関心の遺伝子のポリA、SV40またはβ-ヘモグロビン(HBB2)のポリAで、好ましくはヒトFKRPをコードする配列の3’にあるもの。好ましい例として、HBB2のポリAを配列番号15に開示する;
・エンハンサー配列;
・ヒトFKRPコード配列の発現が望ましくない(例えばそれが毒性でありうる)、標的でない組織において、該配列の発現を抑制することのできる、miRNA標的配列。好ましくは、対応するmiRNAは骨格筋には存在せず、場合により心臓には存在しない。
・配列番号10または11のヌクレオチド494~638に相当する5’ITR配列(配列番号12);それに続く、
・配列番号10または11のヌクレオチド639~1699に相当するヒトデスミンプロモーター(配列番号13);それに続く、
・配列番号10または11のヌクレオチド1700~2151に相当する、HBB2イントロンとそれに続くコンセンサスKozak配列(配列番号14);それに続く、
・ヒトFKRPをコードするポリヌクレオチド、例えば配列番号3または4または5または6または7または8;ここで、配列番号3または4の場合、これは配列番号10または11のヌクレオチド2152~3639に相当する;それに続く、
・配列番号10または11のヌクレオチド3640~4405に相当する、HBB2ポリA配列(配列番号15);それに続く、
・配列番号10または11のヌクレオチド4406~4550に相当する、3’ITR配列(配列番号16)。
・上記に開示した本発明のポリヌクレオチドまたは前記ポリヌクレオチドを含むベクターを含む、細胞。
該細胞は、任意のタイプの細胞、すなわち原核生物または真核生物の細胞でありうる。該細胞は、該ベクターの増殖のために使用することができるか、またはさらに宿主もしくは対象に導入(例えば移植)することができる。該ポリヌクレオチドまたはベクターは、細胞に、当分野で知られる任意の方法で、例えばトランスフォーメーション、エレクトロポレーションまたはトランスフェクションによって導入することができる。細胞から誘導された小胞を用いることもできる。
・上記に開示した本発明のポリヌクレオチド、前記ポリヌクレオチドを含むベクター、または前記ポリヌクレオチドもしくは前記ベクターを含む細胞を含む、トランスジェニック動物、好ましくは非ヒト・トランスジェニック動物。
・流速1~10mL/分、好ましくは1~5mL/分、例えば3mL/分;
・総注射体積は、対象の体重1kg当たりベクター製剤1~20mLの間、好ましくは5mLでありうる。注射体積は、全血液体積の10%を超えるべきではなく、好ましくは約6%である。
下記実験例によって、本発明をさらに説明する。実験例は、単に説明を目的とするものであり、限定を意図するものではない。
新規なヒトFKRP配列の設計
ヒトFKRPコード配列である配列番号2を、下記ルールにしたがって改変した:
・コード領域中に存在するセンスおよびアンチセンスフレームシフトATGを禁止する変異を、位置429(アンチセンス;フェーズ+1)、位置546(センス;フェーズ+1)、位置819(アンチセンス;フェーズ+1)および/または位置1431(アンチセンス;フェーズ+1)において導入する;
・場合により、例えばSharp et al. (1988)に開示されるような、コドン頻度表にしたがう;
・新たなオープンリーディングフレーム(ORF)の形成を伴わない;
・場合により、CpGアイランドの形成を回避するためにCGモチーフを置換する;
・場合により、GC%を低下させる;
・場合により、配列番号2の位置553~559に存在するステムループを改変する。
ヒトFkrp遺伝子のコード配列(配列番号2)を、古典的な遺伝子合成サービス法を用いて合成し、AAV2のITR、ヒトデスミンプロモーター、HBB2イントロンとそれに続くKozak配列、およびHBB2ポリA(ヘモグロビンサブユニットβ2ポリアデニル化シグナル)を含むプラスミド(pUC57)に導入した。
フォワード:CCAGGCGAGGAGAAACCA(配列番号17);
リバース:CTTGACTCCACTCAGTTCTCTTGCT(配列番号18);および
プローブ:CTCGCCGTAAAACATGGAAGGAACACTTC(配列番号19)
細胞ペレットおよび筋組織を、EDTA不含有のCompleteプロテアーゼインヒビターカクテル(Roche, Bale, Switzerland)を補充したRIPA溶解バッファー(Thermo Fisher Scientific, Waltham, MA, USA)中で、機械的にホモジナイズした。サンプルに含まれた核酸を、ベンゾナーゼ(Sigma, St. Louis, MO, USA)を用いて37℃で15分間インキュベートすることにより分解した。
1箇月齢のマウスを用いた。本試験のすべての動物の扱いは、動物実験の人道的管理と使用のための欧州のガイドラインに従い、動物に対するすべての手順は、Genopoleの倫理委員会により承認された。
エスケープ試験:
エスケープ試験(Carlson and Makiejus, 1990)では、マウスの全身的な強さが評価される。すなわち、マウスを、長さ30cmの管の入り口に面したプラットフォーム上に置く。尾に巻いたカフを、固定した力変換器に連結し、尾を軽くつまむことによって、マウスを力変換器とは逆方向の管内に逃れるように誘導する。この前方への逃避によって短時間の力のピークが誘導され、5つの最も高い力ピークの平均を体重で正規化して解析する。
力変換器ADInstrument MLT1030 serial 810
ソフトウェアADinstrument Labchart7
文献(Vignaud et al., 2005)に記載されるように、in situ筋収縮の測定により、骨格筋機能が評価される。動物をケタミン(100mg/kg)およびキシラジン(10mg/kg)の腹腔内注射によって麻酔し、深い麻酔を維持するために必要に応じて追加の用量を投与する。膝および脚を鉗子およびステンレススチール製ピンで固定する。TA筋を露出し、遠位の健を切断して力変換器(Aurora Scientific, Dublin, Ireland)につなぐ。座骨神経を近位で圧迫し、遠位で、バイポーラー銀電極で長さ0.1msの最大上の方形波パルスにより刺激する。絶対最大力を、至適長さ(最大テタニー張力が観測される長さ)において測定する。総筋力を筋肉重量で正規化することによって、比最大力を計算する。
装置Aurora Scientific
センサー305C 5N Cambridge Technology Model 6650 n°X11271243Y
ソフトウェアASI 610A Dynamic muscle Control
注射したマウスを、機能試験の直後に殺した。骨格筋のサンプルを採り、冷却イソペンタン中で凍結した。横断凍結切片をヘマトキシリン-フロキシン-サフラン(HPS)で染色し、中心核を有する線維の計数に使用した。中心核を有する線維の数を切片面積に対して記録して、中心核形成指数を得た。
I.新規なヒトFKRP配列の設計
FKRPコード配列における改変の効果を評価するために、配列番号2の配列から誘導した、配列番号1のヒトFKRPタンパク質をコードする一連の配列を設計し合成した。それら配列の主な特徴を表1にまとめる:
遺伝子導入後のFKRP発現のウエスタンブロットにより得られた結果を図2Aに示す。異なるコンストラクト(wtおよび最適化)から発現されたFKRPタンパク質は、予想された大きさ(58kDa)を有する。さらに、改変FKRP導入遺伝子は、野生型配列と比較して、FKRPタンパク質の発現を増加させる。得られたバンドの強度を定量化し、GAPDH標準に対して正規化した。定量化データは、FKRPwtと比較してhFKRP-OPTcompが5倍の増加をもたらしたことを示している(図2B)。
最有望の配列、すなわちFKRP-OPTcomp(配列番号4)について、インビボ効果を、FKRP欠損マウスモデルにおいて試験した。
本研究は、ヒトFKRP導入遺伝子の配列最適化によって、マウスにおいて、該導入遺伝子を含むAAVベクターの筋肉内注射後のFKRP発現レベルを改善できることを示している。この発現レベル向上は、処置効率を改善し、および/または治療プロダクトの注射用量の低減を可能にするから、処置および臨床上興味深い。
Claims (12)
- 配列番号3、配列番号4または配列番号6の配列を含む、ポリヌクレオチド。
- 配列番号3、配列番号4または配列番号6の配列からなる、請求項1に記載のポリヌクレオチド。
- 請求項1または2に記載のポリヌクレオチドを含むベクター。
- アデノ随伴ウイルス(AAV)ベクター、好ましくは血清型2、8または9のAAVベクターである、請求項3に記載のベクター。
- 前記AAVベクターが、血清型9のもの、好ましくは血清型2/9のものである、請求項4に記載のベクター。
- 配列番号10、配列番号11、配列番号21の配列、またはそれとの同一性が少なくとも90%である配列を含む、請求項3~5のいずれかに記載のベクター。
- 請求項1または2に記載のポリヌクレオチド、または請求項3~6のいずれかに記載のベクターを含む細胞。
- 請求項1または2に記載のポリヌクレオチド、または請求項3~6のいずれかに記載のベクター、または請求項7に記載の細胞を含む非ヒト・トランスジェニック動物。
- 医薬としての使用のための、請求項1または2に記載のポリヌクレオチド、または請求項3~6のいずれかに記載のベクター、または請求項7に記載の細胞を含む組成物。
- 請求項1または2に記載のポリヌクレオチド、または請求項3~6のいずれかに記載のベクター、または請求項7に記載の細胞を含む医薬組成物。
- FKRP欠損に関連付けられるか、またはα-ジストログリカン(α-DG)のグリコシル化異常により誘導される病態の処置における使用のための、請求項10に記載の組成物。
- 前記病態が、肢帯型筋ジストロフィー2I型(LGMD2I)、先天性筋ジストロフィー1C型(MDC1C)、ウォーカー-ワールブルグ症候群(WWS)および筋-眼-脳病(MEB)からなる群から選択され、好ましくはLGMD2Iである、請求項11に記載の使用のための組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305894.2 | 2017-07-07 | ||
EP17305894 | 2017-07-07 | ||
PCT/EP2018/068420 WO2019008157A1 (en) | 2017-07-07 | 2018-07-06 | NOVEL POLYNUCLEOTIDES ENCODING HUMAN FKRP PROTEIN |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020530275A JP2020530275A (ja) | 2020-10-22 |
JP7141417B2 true JP7141417B2 (ja) | 2022-09-22 |
Family
ID=59363068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019572563A Active JP7141417B2 (ja) | 2017-07-07 | 2018-07-06 | ヒトfkrpタンパク質をコードする新規ポリヌクレオチド |
Country Status (6)
Country | Link |
---|---|
US (2) | US11596698B2 (ja) |
EP (1) | EP3648783A1 (ja) |
JP (1) | JP7141417B2 (ja) |
CN (1) | CN110944656B (ja) |
CA (1) | CA3069045A1 (ja) |
WO (1) | WO2019008157A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3122319A1 (en) * | 2018-12-21 | 2020-06-25 | Genethon | Expression cassettes for gene therapy vectors |
CN114521143A (zh) * | 2019-09-19 | 2022-05-20 | 吉尼松公司 | 减轻fkrp心脏毒性的基因治疗表达系统 |
US20230374542A1 (en) * | 2020-10-07 | 2023-11-23 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21) |
WO2022147490A1 (en) * | 2021-01-04 | 2022-07-07 | The University Of North Carolina At Chapel Hill | Optimized fukutin-related proteins (fkrp) and methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016138387A1 (en) | 2015-02-27 | 2016-09-01 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System | Methods and compositions for treating dystroglycanopathy disorders |
JP2017513501A (ja) | 2014-04-25 | 2017-06-01 | ジェネトン | 高ビリルビン血症の処置 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
DK1310571T3 (da) | 2001-11-13 | 2006-06-19 | Univ Pennsylvania | Fremgangsmåde til identifikation af ukendte adeno-associerede virussekvenser (AAV-sekvenser) og et kit til fremgangsmåden |
EP1453547B1 (en) | 2001-12-17 | 2016-09-21 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor |
ES2411479T3 (es) | 2003-09-30 | 2013-07-05 | The Trustees Of The University Of Pennsylvania | Clados de virus adeno-asociados (AAV), secuencias, vectores que los contienen, y usos de los mismos |
WO2014144907A1 (en) * | 2013-03-15 | 2014-09-18 | Children's Medical Center Corporation | Methods and compounds for the treatment of dystroglycanopathies |
-
2018
- 2018-07-06 WO PCT/EP2018/068420 patent/WO2019008157A1/en unknown
- 2018-07-06 EP EP18736914.5A patent/EP3648783A1/en active Pending
- 2018-07-06 CN CN201880045606.3A patent/CN110944656B/zh active Active
- 2018-07-06 CA CA3069045A patent/CA3069045A1/en active Pending
- 2018-07-06 JP JP2019572563A patent/JP7141417B2/ja active Active
- 2018-07-06 US US16/628,650 patent/US11596698B2/en active Active
-
2023
- 2023-03-02 US US18/177,446 patent/US20230321277A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017513501A (ja) | 2014-04-25 | 2017-06-01 | ジェネトン | 高ビリルビン血症の処置 |
WO2016138387A1 (en) | 2015-02-27 | 2016-09-01 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System | Methods and compositions for treating dystroglycanopathy disorders |
Also Published As
Publication number | Publication date |
---|---|
CN110944656B (zh) | 2024-05-03 |
WO2019008157A1 (en) | 2019-01-10 |
CA3069045A1 (en) | 2019-01-10 |
US11596698B2 (en) | 2023-03-07 |
US20230321277A1 (en) | 2023-10-12 |
CN110944656A (zh) | 2020-03-31 |
US20210338837A1 (en) | 2021-11-04 |
JP2020530275A (ja) | 2020-10-22 |
EP3648783A1 (en) | 2020-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7141417B2 (ja) | ヒトfkrpタンパク質をコードする新規ポリヌクレオチド | |
JP6656240B2 (ja) | ジストロフィー病態の効率的な全身処置 | |
US10752898B2 (en) | Effective gene therapy tools for dystrophin exon 53 skipping | |
ES2876422T3 (es) | Sistema de expresión para una terapia genética selectiva | |
KR20190005223A (ko) | 아데노-관련 바이러스 변이체 캡시드 및 그 용도 | |
JP2017513861A (ja) | 末梢性ニューロパチー及び運動ニューロン疾患の治療方法 | |
US20150045416A1 (en) | Methods and Compositions for Gene Delivery | |
JP2023504735A (ja) | ヒトmecp2遺伝子を発現するように設計されたトランスジーンカセット | |
KR20210124300A (ko) | Cln3 폴리뉴클레오티드의 아데노-관련 바이러스 전달 | |
US20230256117A1 (en) | Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg | |
US20230270885A2 (en) | Gene therapy expression system alleviating cardiac toxicity of fkrp | |
CN116194587A (zh) | 一种新的肌肉特异性启动子 | |
KR20190028389A (ko) | 디스펄린병증의 치료를 위한 절단형 디스펄린 | |
WO2021146260A1 (en) | Methods of treating phenylketonuria | |
US20220389450A1 (en) | Vector system | |
IL294627A (en) | Methods for treating phenalactonuria | |
JP2024521713A (ja) | Kcnv2変異体及びその使用 | |
NZ713958A (en) | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases | |
NZ753155B2 (en) | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210908 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220629 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220726 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220824 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220909 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7141417 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |